Company Overview and News
Shares of Madrigal Pharmaceuticals catapulted to new high due to robust phase 2 data reporting for NASH. (99-1)
RnRMarketResearch.com adds "Liver Fibrosis - Pipeline Review, H1 2017" therapeutic market research report of 200 pages with latest updates, data and information to its online business intelligence library. (0-2)
M&A activity is seeing a noticeable uptick to start the year compared to a punk 2016 for transactions. (0-1)
REUTERS: Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to US$1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease. (0-1)
The term 'platform technology' gets a lot of play, some of it hype, but when an emerging and scientifically sound biotech company shows promise of multiple uses for its core drug, investors should take notice. This is the case with Can-Fite BioPharma Ltd. (NYSEMKT:CANF), who last month released convincing preclinical data that its CF102, currently in trials for a common form of liver cancer, has a beneficial effect on non-alcoholic steatohepatitis (NYSEARCA:NASH), an insidious disease not readily manifested, making it all the more dangerous.
RnRMarketResearch.com adds "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016" market research report with comprehensive information on NASH therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Global NASH market report says progressive numbers of liver disorders along with rise in obesity will fuel the demand for NASH (non-alcoholic steatohepatitis) drugs in the coming few years. The NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics.
According to a new market report published by Transparency Market Research "Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025", the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025. (0-1)
NEW YORK: French drugmaker Genfit SA on Thursday said it would begin a midstage trial this year of its experimental drug elafibranor to treat primary biliary cholangitis, a chronic disease in which bile ducts in the liver are gradually destroyed. (0-1)
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton